Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.79 |
| ▸ | USP2 | O75604 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | HPGD | P15428 | 2/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.79 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | AQP1 | P29972 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piretanide SCHEMBL230684 | 0.93 | ALDH1A1 (0.67) | KDM4EALDH1A1HSD17B10USP2LMNA | |
| Piretanide SCHEMBL30230376 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10USP2LMNA | |
| Piretanide SCHEMBL49473 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10USP2LMNA | |
| Piretanide SCHEMBL1741994 | 0.89 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10USP2LMNA | |
| SCHEMBL2741891 | 0.88 | KDM4E (0.98) | KDM4EALDH1A1HSD17B10USP2LMNA | |
| Piretanide SCHEMBL9837127 | 0.88 | KDM4E (0.98) | KDM4EALDH1A1HSD17B10USP2LMNA | |
| Piretanide SCHEMBL7895002 | 0.87 | KDM4E (0.95) | KDM4EALDH1A1HSD17B10USP2LMNA | |
| Piretanide SCHEMBL18075706 | 0.87 | KDM4E (0.95) | KDM4EALDH1A1HSD17B10USP2LMNA | |
| SCHEMBL11542770 | 0.87 | KDM4E (0.95) | KDM4EALDH1A1HSD17B10USP2LMNA | |
| Piretanide SCHEMBL251053 | 0.87 | KDM4E (0.82) | KDM4EALDH1A1HSD17B10USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137875-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | OTOLANUM AG (CH) | 2021-05-13 | — | — | US | claimed |
| US-20180360797-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | EBERHARD-KARLS-UNIVERSITAT TUBINGEN UNIVERSITATSKLINIKUM (DE) | 2018-12-20 | — | — | US | claimed |
| US-20160271098-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | EBERHARD-KARLS-UNIVERSITAT TUBINGEN UNIVERSITATSKLINIKUM (DE) | 2016-09-22 | — | — | US | claimed |
| US-20150044200-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | OTOLANUM AG (CH) | 2015-02-12 | — | — | US | claimed |
| EP-2790686-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | Auris Medical AG (CH) | 2014-10-22 | — | — | EP | claimed |
| WO-2013087090-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | AURIS MEDICAL AG (CH) | 2013-06-20 | — | — | WO | claimed |
| US-20120234721-A1 | DIURETIC AND DIURETIC-LIKE COMPOUND ANALOGS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-09-20 | — | — | US | claimed |
| US-20120108640-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2012-05-03 | — | — | US | claimed |
| EP-2389371-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | Neurotherapeutics Pharma, Inc. (US) | 2011-11-30 | — | — | EP | claimed |
| WO-2010085352-A2 | BUMETANIDE, FUROSEMIDE, PIRETANIDE, AZOSEMIDE, AND TORSEMIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2010-07-29 | — | — | WO | claimed |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. | 2009-08-27 | — | — | US | claimed |
| EP-1874286-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | NEUROTHERAPEUTICS PHARMA INC (US) | 2009-07-01 | — | — | EP | claimed |
| EP-1951702-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1937242-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NeuroTherapeutics Pharma, Inc. (US) | 2008-07-02 | — | — | EP | claimed |
| EP-1874286-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | Neurotherapeutics Pharma LLC (US) | 2008-01-09 | — | — | EP | claimed |
| US-20070149526-A1 | Diuretic and diuretic-like compound analogs | NEUROTHERAPEUTICS PHARMA, L.L.C. | 2007-06-28 | — | — | US | claimed |
| WO-2007047698-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| WO-2007047447-A2 | DIURETIC-LIKE COMPOUND ANALOGS USEFUL FOR REGULATION OF CENTRAL NERVOUS SYSTEM DISORDERS | NEUROTHERAPEUTICS PHARMA, INC. (US) | 2007-04-26 | — | — | WO | claimed |
| WO-2006110187-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANXIETY DISORDERS | NEUROTHERAPEUTICS PHARMA LLC (US) | 2006-10-19 | — | — | WO | claimed |
| US-20060089350-A1 | Methods and compositions for the treatment of neuropsychiatric disorders | NEUROTHERAPEUTICS PHARMA LLC (US) | 2006-04-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180360797-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | SLC6A1, SLC6A11, SLC6A13 | KDM4E 3359/4885ALDH1A1 1235/4885HSD17B10 2894/4885 |
| US-20120234721-A1 | DIURETIC AND DIURETIC-LIKE COMPOUND ANALOGS | AQP4, AVPR2, AQP1 | KDM4E 3557/4885ALDH1A1 687/4885HSD17B10 357/4885 |
| US-20160271098-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | SLC6A1, SLC6A11, SLC6A13 | KDM4E 3398/4885ALDH1A1 1244/4885HSD17B10 2728/4885 |
| US-20060089350-A1 | Methods and compositions for the treatment of neuropsychiatric disorders | SLC1A2, SLC18A2, GRIN2C | KDM4E 1867/4885ALDH1A1 1109/4885HSD17B10 1793/4885 |
| US-20210137875-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | SLC6A1, SLC6A13, SLC6A11 | KDM4E 3327/4885ALDH1A1 1240/4885HSD17B10 2882/4885 |
| US-20070149526-A1 | Diuretic and diuretic-like compound analogs | AQP4, AVPR2, AQP1 | KDM4E 3557/4885ALDH1A1 687/4885HSD17B10 357/4885 |
| US-20090215754-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC AND ADDICTIVE DISORDERS | SLC6A2, SLC1A2, SLC18A2 | KDM4E 1504/4885ALDH1A1 701/4885HSD17B10 1934/4885 |
| US-20120108640-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | SLC1A2, SLC18A2, GRIN2C | KDM4E 1867/4885ALDH1A1 1109/4885HSD17B10 1793/4885 |
| US-20150044200-A1 | TREATMENT OF TINNITUS THROUGH MODULATION OF CHLORIDE CO-TRANSPORTER NKCC1 IN THE AUDITORY SYSTEM | SLC6A1, SLC6A11, SLC6A13 | KDM4E 3378/4885ALDH1A1 1220/4885HSD17B10 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.